• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by agilon health inc. (Amendment)

    2/8/24 4:01:58 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email
    SC 13G/A 1 d658066dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    agilon health, inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    00857U 10 7

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    * 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00857U 10 7

     

     1   

     NAMES OF REPORTING PERSONS

     

     CD&R Vector Holdings, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     (a) ☐  (b) ☐

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     100,000,000

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     100,000,000

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     100,000,000

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     24.6%(1)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    Based on 406,040,924 shares of common stock outstanding as of October 27, 2023, as reported in the Issuer’s quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on November 2, 2023 (the “Form 10-Q”).


    CUSIP No. 00857U 10 7

     

     1   

     NAMES OF REPORTING PERSONS

     

     CD&R Investment Associates IX, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     (a) ☐  (b) ☐

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     100,000,000

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     100,000,000

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     100,000,000

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     24.6%(1)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO

     

    (1)

    Based on 406,040,924 shares of the Issuer’s common stock outstanding as of October 27, 2023, as reported in the Issuer’s Form 10-Q.


    CUSIP No. 00857U 10 7

     

     1   

     NAMES OF REPORTING PERSONS

     

     CD&R Associates IX, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     (a) ☐  (b) ☐

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     100,000,000

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     100,000,000

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     100,000,000

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     24.6%(1)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     PN

     

    (1)

    Based on 406,040,924 shares of the Issuer’s common stock outstanding as of October 27, 2023, as reported in the Issuer’s Form 10-Q.


    CUSIP No. 00857U 10 7

     

    Item 1.

     

      (a)

    Name of Issuer:

    agilon health, inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    6210 E. Highway 290, Suite 450

    Austin, Texas 78723

    Item 2.

     

      (a)

    Name of Person Filing:

    This filing is being made on behalf of (each, a “Reporting Person”):

    CD&R Vector Holdings, L.P.

    CD&R Investment Associates IX, Ltd.

    CD&R Associates IX, L.P.

     

      (b)

    Address of Principal Business Office or, if none, Residence

    The principal business office of each Reporting Person is c/o Clayton, Dubilier & Rice, LLC, 375 Park Avenue, New York, New York 10152.

     

      (c)

    Citizenship:

    Each Reporting Person is organized under the laws of the Cayman Islands.

     

      (d)

    Title of Class of Securities:

    Common stock, par value $0.01 per share (the “Common Stock”)

     

      (e)

    CUSIP Number:

    00857U 10 7

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e)    ☐    An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Not Applicable.

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned:

    See the responses to Item 9 on the attached cover pages.

     

    (b)

    Percent of class:

    See the responses to Item 11 on the attached cover pages. The percentages reported in Item 11 on the attached cover pages are based upon an aggregate of 406,040,924 shares of Common Stock outstanding as of October 27, 2023, as reported in the Issuer’s quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission on November 2, 2023.

     

    (c)

    Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote:

    See the responses to Item 5 on the attached cover pages.

    (ii) Shared power to vote or to direct the vote:

    See the responses to Item 6 on the attached cover pages.

    (iii) Sole power to dispose or to direct the disposition:

    See the responses to Item 7 on the attached cover pages.

    (iv) Shared power to dispose or to direct the disposition:

    See the responses to Item 8 on the attached cover pages.


    100,000,000 shares of Common Stock are held directly by CD&R Vector Holdings, L.P. and may be deemed to be beneficially owned by CD&R Investment Associates IX, Ltd., as the general partner of CD&R Vector Holdings, L.P. CD&R Investment Associates IX, Ltd. expressly disclaims beneficial ownership of the shares of Common Stock directly held by CD&R Vector Holdings, L.P. Investment and voting decisions with respect to the shares of Common Stock held by CD&R Vector Holdings, L.P. are made by an investment committee of limited partners of CD&R Associates IX, L.P., currently consisting of more than ten individuals, each of whom is also an investment professional of Clayton, Dubilier & Rice, LLC (the “Investment Committee”). All members of the Investment Committee expressly disclaim beneficial ownership of the shares of common stock directly held by CD&R Vector Holdings, L.P. CD&R Investment Associates IX, Ltd. is managed by two directors. Donald J. Gogel and Nathan K. Sleeper, as the directors of CD&R Investment Associates IX, Ltd., may be deemed to share beneficial ownership of the shares of Common Stock directly held by CD&R Vector Holdings, L.P. Such persons expressly disclaim such beneficial ownership.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]:

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    See Item 4 above.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    Not Applicable.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 8, 2024

     

    CD&R VECTOR HOLDINGS, L.P.      

    By: CD&R Investment Associates IX, Ltd., its general partner

     

    /s/ Rima Simson

    Name: Rima Simson

    Title: Vice President, Treasurer and Secretary

    CD&R INVESTMENT ASSOCIATES IX, LTD.      

    /s/ Rima Simson

    Name: Rima Simson

    Title: Vice President, Treasurer and Secretary

    CD&R ASSOCIATES IX, L.P.      

    By: CD&R Investment Associates IX, Ltd., its general partner

     

    /s/ Rima Simson

    Name: Rima Simson

    Title: Vice President, Treasurer and Secretary

    Get the next $AGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    8/6/2025$1.00Buy → Neutral
    Citigroup
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    More analyst ratings

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilon Health downgraded by Bernstein with a new price target

    Bernstein downgraded Agilon Health from Outperform to Mkt Perform and set a new price target of $1.40

    8/20/25 8:21:47 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health downgraded by Citigroup with a new price target

    Citigroup downgraded Agilon Health from Buy to Neutral and set a new price target of $1.00

    8/6/25 7:57:52 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health upgraded by Citigroup with a new price target

    Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

    4/25/25 8:23:09 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health to Participate in the 2025 Jefferies Healthcare Services Conference

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference on Tuesday, September 30 at 8:45am ET. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physici

    9/16/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

    4/A - agilon health, inc. (0001831097) (Issuer)

    4/3/25 7:40:25 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:42:37 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Markets Officer Shaker Benjamin bought 11,786 shares and covered exercise/tax liability with 4,143 shares, increasing direct ownership by 2% to 457,058 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:41:48 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 406 shares, decreasing direct ownership by 0.35% to 114,752 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/19/25 5:39:24 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Legal Officer Zamore Denise covered exercise/tax liability with 915 shares, decreasing direct ownership by 0.21% to 443,125 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/5/25 5:10:48 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Schwaneke Jeffrey A. covered exercise/tax liability with 46,099 shares, decreasing direct ownership by 4% to 1,075,122 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    7/3/25 4:08:23 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    9/5/25 5:41:23 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SCHEDULE 13G filed by agilon health inc.

    SCHEDULE 13G - agilon health, inc. (0001831097) (Subject)

    8/29/25 11:00:27 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    8/13/25 12:56:59 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Financials

    Live finance-specific insights

    View All

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Second Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the second quarter 2025 after the market closes on Tuesday, August 5, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 938716. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of t

    7/22/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report First Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the first quarter 2025 after the market closes on Tuesday, May 6, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 095319. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the ca

    3/25/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Leadership Updates

    Live Leadership Updates

    View All

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

    Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

    7/10/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Names Jeff Schwaneke New Chief Financial Officer

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

    6/5/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/13/24 12:49:26 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/8/24 10:52:39 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/6/24 4:47:14 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care